Lung Cancer News and Research

Latest Lung Cancer News and Research

State of health, not age, should decide treatment for cancer

In a study of patients 65 and older with non-small-cell lung cancer (NSCLC), younger patients were more likely to receive treatment than older patients, regardless of overall health and prognosis.

3 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Beta-carotene-derived molecules have opposite effect in the body

New research suggests that there could be health hazards associated with consuming excessive amounts of beta-carotene.

2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

Astounding lack of public awareness about lung cancer

An astounding lack of public awareness about lung cancer has been revealed in a Cancer Research UK study, published today.

30 Apr 2012

New class of drugs hold promise against aggressive forms of pancreatic cancer

Cancer Research UK-funded scientists have shown how a promising new class of drugs might be used to treat aggressive forms of pancreatic cancer, according to a study published in Nature.

30 Apr 2012

MCC researchers aim to improve cancer patient's quality of life and care

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

30 Apr 2012

Research roundup: Practice guidelines may not stop defensive medicine; English language ability tied to hospital readmission rates

The Value of Clinical Practice Guidelines As Malpractice "Safe Harbors" -- Overspending on health care has frequently been attributed to doctors practicing defensive medicine -- ordering extra tests, for example -- so that they avoid malpractice lawsuits. The authors of this brief write that while some have said clinical guidelines "should give caregivers a liability 'safe harbor,' shielding them from any malpractice claim for failing to provide services not included in the guideline."

27 Apr 2012

Combination of Velcade and Fasudil could treat NSCLC

A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today.

27 Apr 2012

Aspirin can reduce chance of dying from bowel cancer by 30%

Taking aspirin after being diagnosed with bowel cancer can reduce the chance of dying from the disease by 30 per cent, new research shows today.

27 Apr 2012

Aspirin reduces bowel cancer death and lung cancer incidence: Research suggests

There is previous evidence suggesting aspirin might prevent certain cancers from developing in the first place. And more recent work suggests it might also work as a cancer therapy - slowing down or preventing a cancer's spread. But the drug can also have unpleasant and dangerous side effects, causing irritation of the stomach lining and internal bleeds in a very small minority of patients.

26 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

MMP-10 gene plays a dual role in lung cancer

A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida.

25 Apr 2012

Cancer, genetic screenings under scrutiny

Various news outlets covered issues around cancer screening, diagnosis and treatment.

23 Apr 2012

Study finds survival advantage for Hispanic lung cancer patients

A new analysis has found that Hispanic lung cancer patients seem to live longer than white or black patients. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that, as with several other types of cancer, certain yet-to-be-defined genetic and/or environmental factors put Hispanic patients at a survival advantage.

23 Apr 2012

NZ all in for plain tobacco packaging

New Zealand’s cabinet has agreed in principle to introduce plain packaging for all tobacco products in New Zealand, following a similar move in Australia.

22 Apr 2012

VeriStrat test may be useful for NSCLC clinical decision-making

Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib.

21 Apr 2012

Research roundup: Caring for dual eligibles; Antitrust policy and the health law

Using data from the Centers for Disease Control and Prevention (CDC), this report notes a systematic difference in life expectancy across region and race. "Within in each sex-race group, there are striking geographical differences in the probability of survival to age 70. ... These differences are larger for males than females within each race and larger for blacks than whites within each sex."

21 Apr 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012